The Hartford County Maryland Health Department is making the path to Opioid Use Disorder (OUD) recovery more attainable for local patients. The first step, providing patients access to the Sparrow Therapy System to overcome withdrawal symptoms. 

Ending opioid addiction in the Lowcountry is the goal of the Medical University of South Carolina staff as they get ready to launch a multi-year clinical trial to test a new device aimed at helping patients with opioid withdrawals.

Battelle announced today that it entered into a collaborative agreement with Spark Biomedical to jointly run a pilot clinical study. Through the joint study, the two companies aim to advance the remote detection and treatment of opioid use disorder (OUD) using wearable biosensors.

A clinical trial in Dallas will test new technology that could help infants overcome withdrawal from exposure to opioids while in the womb.

Spark Biomedical created the FDA-approved Sparrow Therapy System. It’s essentially an earpiece that sends mild electrical pulses to the brain to help alleviate the withdrawal symptoms that patients go through while they’re detoxing, like insomnia, tremors, chills and sweating, bone pain, mood swings, and more.

D CEO and Dallas Innovates are proud to announce the finalists for its third annual Innovation Awards and Spark Biomedical is on the list of contenders for Startup Innovator of the Year.

FinPay LLC, a recognized leader in pre-care payments and patient engagement, announced an agreement with Spark Biomedical, Inc., a Texas-based medical device company and developer of the first FDA-cleared, drug-free, personalized, wearable neurostimulation solution for opioid withdrawal — the Sparrow Therapy System. 

The medical device startup developed the Sparrow Therapy System, a wearable neurostimulation device that provides drug-free opioid withdrawal relief. What's next? Spark also has another device in clinical trials to help the youngest victims of addiction—babies.